More on 688180
News
- Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
- Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)
- Junshi Biosciences meets primary endpoints in lung cancer study
- Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
- Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
- Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
- Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
- Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Entities mentioned with 688180
- FDA | View Related Stories »
- PDUFA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- AdCom | View Related Stories »
- S1 | View Related Stories »
- Stock Buyback | View Related Stories »
- IPO | View Related Stories »
- Show More...
